anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND OBJECTIVE: Tibial nerve stimulation (TNS) has long been used to effectively treat lower urinary tract dysfunction (LUTD). Although numerous studies have concentrated on TNS, its mechanism of action remains elusive. This review aimed to concentrate on the mechanism of action of TNS against LUTD.
MATERIALS AND METHODS: A literature search was performed in PubMed on October 31, 2022. In this study, we introduced the application of TNS for LUTD, summarized different methods used in exploring the mechanism of TNS, and discussed the next direction to investigate the mechanism of TNS.
RESULTS AND CONCLUSIONS: In this review, 97 studies, including clinical studies, animal experiments, and reviews, were used. TNS is an effective treatment for LUTD. The study of its mechanisms primarily concentrated on the central nervous system, tibial nerve pathway, receptors, and TNS frequency. More advanced equipment will be used in human experiments to investigate the central mechanism, and diverse animal experiments will be performed to explore the peripheral mechanism and parameters of TNS in the future.
FIELD: medicine. ^ SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used for preparation of medication for treatment of cancer with expression of TLR3 in patient. For this purpose used is TLR3 agonist in combination with type I interferon in low dose. Impact efficiency is conditioned by synergic effect between TLR3 agonist and interferon. ^ EFFECT: invention allows to affect tumour due to induction of apoptosis in cancer cell TLR3 expressing. ^ 18 cl, 14 ex, 1 dwg
This is a retrospective cohort study recruiting surgical patients at Galdakao-Usansolo Hospital between 2019 and 2022. We used anonymized patient level data from patients in waiting list to be intervened in four public hospitals in Basque Country.
BACKGROUND: In comparison to primary reverse shoulder arthroplasty (RSA) procedures, revision arthroplasty can be a longer and more complex procedure leading to an increased risk of complications. The reported rates of infection in primary RSA range from 1% to 19% and the cost impact on patients and health care systems is significant, leading to multiple revision surgeries. The purpose of this study was to evaluate the postoperative outcomes, complications, and revision rates for revision reverse shoulder arthroplasty (rRSA) due to infection compared with rRSA for noninfectious causes.
METHODS: Patients who underwent rRSA between 2009 and 2020 by a single fellowship-trained orthopedic surgeon at a single institution were retrospectively identified through a prospectively collected database. Patients were separated into 2 cohorts based on revision diagnosis: (1) rRSA due to infection (rRSAi) and (2) rRSA due to noninfectious causes (rRSAn). Patient-reported outcome scores (PROs), including the Simple Shoulder Test, Constant score, American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form score, University of California-Los Angeles shoulder score, Shoulder Arthroplasty Smart score, and active range of motion (ROM) were collected preoperatively and at a minimum 1-year follow-up. Postoperative complications and revision rates were also collected.
RESULTS: A total of 93 patients (n = 19 rRSAi group, n = 74 rRSAn group) with a mean age of 68 years were included in this analysis. All baseline demographics were comparable between groups. No significant differences were found in preoperative or postoperative PROs and ROM between the 2 groups. Postoperative complication rates and revision rates were comparable between the groups.
CONCLUSION: RSA due to infection results in similar patient-reported outcome scores, range of motion, and revision rates when compared to rRSA for noninfectious causes. Our results suggest that despite the unique challenges associated with rRSA for infection, patient outcomes do not differ from cases attributed to noninfectious causes. More efforts are warranted to further validate and contextualize these findings, considering the protentional influence of patient-specific and implant-specific factors.
Subject will receive CAB 30 mg tablet once daily oral dose for 28 days (4 weeks) followed by a washout period of 14 to 42 days. After the washout, subject will receive a single dose of CAB LA 600 mg IM to gluteal region.
BACKGROUND: Numerous researches have indicated a correlation between the intake of dietary micronutrients and the occurrence of constipation. Nevertheless, the correlation between constipation and vitamin B1 remains uninvestigated. The main aim of this research was to examine the association between chronic constipation and the consumption of vitamin B1 in the diet among adult participants of the National Health and Nutrition Examination Survey (NHANES).
METHODS: This study used data from the NHANES, a survey on health and nutrition conducted between 2005 and 2010. The respondents' dietary information was gathered by utilizing the 24-hour dietary records. Various statistical analyses, such as multiple logistic regression, subgroup analysis, and curve-fitting analysis, were employed to investigate the correlation between dietary intake of vitamin B1 and chronic constipation.
RESULTS: In the trial, there were 10,371 participants, out of which 1,123 individuals (10.8%) were identified as having chronic constipation. Fully adjusted multiple logistic regression analyses showed that increasing dietary intake of vitamin B1 (OR = 0.87, 95% CI: 0.77-0.99) was significantly associated with a reduced risk of constipation. Following adjustment for multiple variables in Model 3, the odds ratio (OR) and 95% confidence interval (CI) for the third tertile, in comparison to the first tertile (reference group), was 0.80 (0.65, 0.99). In addition, subgroup analyses and interaction tests showed a significant inverse association between vitamin B1 intake and the prevalence of constipation, especially among men, non-hypertensive, and non-diabetic individuals (all P-values less than 0.05).
CONCLUSION: This research uncovered an inverse correlation between the consumption of vitamin B1 in the diet and the occurrence of chronic constipation. One potential explanation for this phenomenon is that the consumption of vitamin B1 in one's diet is linked to the softening of stools and an augmented occurrence of colonic peristalsis. Additional extensive prospective research is required to thoroughly examine the significance of thiamine in long-term constipation.
Use of a composition comprising cell membrane, or hydrophobic peptides derived from said cell membrane, for the reduction of lipolytic activity, retardation of fat digestion, suppression of appetite, decrease of body weight and/or lowering of blood lipids. Satiety for fat is mainly driven from the intestine. By the contact of fat with the intestinal mucosa, various satiety peptides are released, thus suppressing appetite and food intake. A reduced rate of fat digestion could optimise the satiety for fat, through prolonged release of satiety peptides. Fat digestion can be retarded by reduction of the lipolytic activity of pancreatic lipase. The examples show that fractions of plant cell membranes (thylakoids) inhibit the lipolytic activity of pancreatic lipase.
After a short video introduction to the bass technique, participants brush their teeth once with a silica toothpaste (Colgate Advanced Whitening, 1 g) for 2 min, starting with the upper front teeth. Thereafter, participants rinse their mouth with of tap water.
After COVID-19, musculoskeletal pain, anxiety, and sleep problems can continue. The study aimed to investigate the effects of strengthening and relaxation exercises on pain, anxiety, and sleep quality. The study was performed at Gaziosmanpaşa Education and Research Hospital with 76 post-covid patients that were randomized into experimental and control groups. Experimental group patients performed strengthening and relaxation exercises 3 times a week for 8 weeks. Control group patients did not perform any program. All participants were assessed with McGill Pain Scale short form (SFMPQ), short-form 36 (SF-36), and Pittsburgh sleep quality index (PSQI) before and after the study.
Somnolence was a commonly reported adverse event reported in patients treated with quetiapine especially during the 3 to 5 day period of initial dose-titration. In schizophrenia trials, somnolence was reported in 18% (89/510) of patients on quetiapine compared to 11% (22/206) of placebo patients.

In acute bipolar mania trials using quetiapine as monotherapy, somnolence was reported in 16% (34/209) of patients on quetiapine compared to 4% of placebo patients. In acute bipolar mania trials using quetiapine as adjunct therapy, somnolence was reported in 34% (66/196) of patients on quetiapine compared to 9% (19/203) of placebo patients. In bipolar depression trials, somnolence was reported in 57% (398/698) of patients on quetiapine compared to 15% (51/347) of placebo patients. Since quetiapine has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle (including automobiles) or operating hazardous machinery until they are reasonably certain that quetiapine therapy does not affect them adversely. Somnolence may lead to falls.
Bone and cartilage toxicity changes resulting in impaired transformation of growth cartilage into new bone were observed in the femur and tibia of rats in a 3-month toxicity study at ≥ 500 mg/kg/day (5 times the human NHC exposure at the RHD). There was no bone or cartilage toxicity in a 1-month toxicity study in rats up to 500 mg/kg/day (4 and 8 times the human NHC exposure at the RHD in females and males, respectively), in dogs dosed for 14 days up to 50 mg/kg/day (similar to the human NHC exposure at the RHD), or in a 1-month toxicity study in mice up to 2,000 mg/kg/day (19 times the human NHC exposure at the RHD). 

Growth cartilage is not present in mature skeletons, therefore the bone and cartilage findings are not relevant for adult humans but may be relevant for pediatric patients [see Warnings and Precautions (5.3) and Use in Specific Populations (8.4)].

Reversible, dose-related bone marrow toxicity affecting all hematopoietic cell lines was observed in dogs at ≥17 mg/kg/day (less than the human NHC exposure at the RHD). Mild decreases in peripheral blood cell and platelet counts were seen after 7 days of molnupiravir treatment progressing to more severe hematological changes after 14 days of treatment. Neither bone marrow nor hematological toxicity was observed in a 1-month toxicity study in mice up to 2,000 mg/kg/day (19 times the human NHC exposure at the RHD) and a 3-month toxicity study in rats up to 1,000 mg/kg/day (9 and 15 times the human NHC exposure at the RHD in females and males, respectively).
PURPOSE:To provide the titled animal specimen useful for the development of drugs and instruments for the remedy of myocardial infarction, especially actue myocardial infraction, by administering a Ca drug for calcium-setting and then a triggering agent to an animal thereby causing acute myocardial necrosis to the animal. CONSTITUTION:An animal is administered with a Ca drug for calcium-setting, preferably an aqueous solution of calcium chloride, and then with a triggering agent to cause the acute myocardial necrosis of the animal and obtain the titled animal specimen. The triggering agent is preferably calcium chloride and an aqueous solution of caffeine. The animal is, e.g. rabbit, dog, etc., preferably rabbit from the view point of reproducibility. An animal specimen afflicted with acute myocardial necrosis and obtained by the present invention can be offered widely as a teaching material. Furthermore, it can be utilized widely for the development of the remedy and the operation instrument for myocardial necrosis.
Vinorelbine is a commonly used drug to treat various malignancies, such as breast cancer, non-small cell lung cancer, and metastatic pleural mesothelioma. Its side effects include severe neutropenia, local phlebitis, gastrointestinal reactions, and neurotoxicity. In view of the scarcity of research on vinorelbine's reproductive toxicity, this study evaluated the impact of vinorelbine ditartrate, a commonly used form of vinorelbine, on oocyte maturation in vitro. Our investigation revealed that vinorelbine ditartrate had no effect on oocyte meiotic resumption. However, it did reduce the rate of first polar body extrusion, suggesting that it could significantly impede the meiotic maturation of oocytes. Vinorelbine ditartrate exposure was found to disturb the regular spindle assembly and chromosome alignment, leading to the continuous activation of the spindle assembly checkpoint (SAC) and a delayed activation of the anaphase-promoting complex/cyclosome (APC/C), ultimately causing aneuploidy in oocytes. Consequently, the administration of vinorelbine is likely to result in oocyte aneuploidy, which can be helpful in providing a drug reference and fertility guidance in a clinical context.
The present invention relates to a composition for skin regeneration, anti-wrinkle, antioxidation, anti-inflammation and skin whitening activities. According to the present invention, orientin promotes collagen synthesis of fibroblasts in the skin and thus has effects of regenerating skin and reducing wrinkles. Orientin inhibits generation of free radicals and thus has an anti-oxidant effect. Orientin also inhibits generation of NO and thus has an anti-inflammatory effect. In addition, orientin inhibits synthesis of melanin and thus has a skin whitening effect. Therefore, the composition can be used as a pharmaceutical composition, an external use skin formulation, a cosmetic composition, or health food. The composition includes a compound represented by chemical formula 1 as an active ingredient.
The device for producing an injectable foam, comprises a blister having a first syringe (102) with a gas, a second syringe (104) with a liquid and a foaming substance, a three way faucet (108) and a third syringe (106), and a machine. Each syringe is designed to fix itself to the three way faucet. The first and second syringes and the faucet are designed to produce the foam, and the third syringe is designed to remove the formed foam. The first and second syringes are aligned one another on the faucet. The machine has a control unit, and a fixation unit. The device for producing an injectable foam, comprises a blister having a first syringe (102) with a gas, a second syringe (104) with a liquid and a foaming substance, a three way faucet (108) and a third syringe (106), and a machine. Each syringe is designed to fix itself to the three way faucet. The first and second syringes and the faucet are designed to produce the foam, and the third syringe is designed to remove the formed foam. The first and second syringes are aligned one another on the faucet. The machine has a control unit, a fixation unit for maintaining the first and second syringe, and a unit for displacing pistons of the first and second syringes respectively in opposite direction. Independent claims are included for: (1) a process for producing injectable foam; and (2) a sealed blister.
Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI). Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
Recent research has emphasized the need for intensive aphasia treatment in order to make the long-term neuroplastic changes associated with recovery and rehabilitation following a stroke. Furthermore, studies have indicated that intensive aphasia treatment is more efficacious than less intensive treatment. Rather than being influenced by such evidence, the reality is that public and private payers are drastically reducing services to persons with aphasia (PWA). Legislation has seriously curtailed the amount of treatment a PWA may receive after hospitalization. Often patients are eligible for only a limited number of treatment sessions over a limited period of time. In some cases, they may not receive any treatment for their communication disorder following their acute hospitalization. Reduced resources (e.g. transportation difficulties, therapist shortages in rural areas) also may severely limit available services.

The Intensive Comprehensive Aphasia Program (ICAP) may be a creative, cost-effective and sustainable option for delivering meaningful and necessary aphasia services. Despite the growing numbers of ICAPs, there is little evidence about their efficacy, effectiveness, or cost-effectiveness. All stakeholders need this evidence. Funding agencies require evidence to make decisions about their investments in aphasia rehabilitation. People with aphasia and their families should have evidence prior to investing their money and time into such programs, and speech and language pathologists have an ethical obligation to provide evidence-based practices.

Based on evidence regarding treatment intensity that has translated principles of neuroplasticity from animal models to stroke recovery, the investigators hypothesize that 60 hours of comprehensive treatment will result in significant improvements in (a) performance-based, (b) client-reported, and (c) surrogate-reported assessments of communication skills, community participation, and health-related quality of life. They also hypothesize that when 60 hours of comprehensive treatment is provided intensively over 3 weeks, the magnitude and rate of improvement as well as the extent to which improvements are maintained will be greater than when the 60 hours of comprehensive treatment is distributed over 15 weeks. Because the investigators hypothesize that the magnitude and rate of improvement will be greater with the intensive ICAP than with the distributed ICAP, they further hypothesize that the intensive ICAP will be more cost-effective than the distributed ICAP.
The present invention relates to biobased glyceryl heptanoate compositions, and preferably glyceryl monoheptanoate compositions, methods of manufacturing the same, as well as applications thereof including the use of the inventive compositions in formulations for cosmetics and other personal care applications. The biobased monoglyceryl monoester (MGME) compositions include a mixture including one or more compounds of Formula (I): R1, R2, and R3 are independently H or C(O)-C6 alkyl. The composition comprises greater than about 60 wt% and less than about 98 wt% glyceryl monoheptanoate. The carbon present in the one or more compounds of Formula (I) is biobased. The composition has an ET50 value of >24 hr when tested as a 1% solution in water according to the EpiDerm Skin Irritation Test (OECD 439). The present invention also relates to microbiostatic concentrates (MBCs) including the disclosed composition.
The invention discloses a health-care wine capable of improving human immunity. The health-care wine capable of improving human immunity comprises the following raw materials in parts by weight: 2-8 parts of Fructus Lycii, 7-10 parts of Rhizoma Chuanxiong, 2-8 parts of Fructus Jujubae, 4-12 parts of Arillus Longan, 5-8 parts of Radix Panacis Quinquefolii and 2-5 parts of Hericium erinaceus (Bull. Ex Fr.) Pers. Extract. The health-care wine capable of improving human immunity is clear in wine liquid and sweet and mellow in taste, has peculiar faint scent of mushrooms, is coordinated in taste and unique in flavor, and has unique effects of improving human immunity and improving sleep.
The invention relates to globules for vaginal and rectal administration for the treatment and prevention of infectious inflammatory diseases in the small pelvis. They comprise dry low-lactose lactic acid product which consists of freeze dry mixture of low lactose skimmed cows' milk, low lactose lactic hydrolysate of over 95% degradation of the lactic casein, low lactose skimmed milk, fermented with selected strains of Lactobacillus delbrueckii subsp. bulgaricus, glucose, fructose, freeze dry monoculture of strain Lactobacillus delbrueckii subsp. bulgaricus with at least 10 mln/g live cells, and crystalline glucose and/or dextrose. The lactobacilli are successfully implanted and propagated in the vaginal and rectal mucous membrane, as a result of which the pH is normalized and the propagation of pathogenic microorganisms is suppressed. In a given case the addition of compositions of oriented action in diseases in the small pelvis is also possible. The globules, also containing estriol or natural estrogens of vegetative origin are particularly efficacious in women with menopause. The globules containing extract of aloe vera with or without estriol (phytoestrogens) have antiphlogistic effect in mycoses. They act astringently and reversibly in haemorrhoids, myomas and hypertrophy of the prostate. The globules, containing extract of Atropa belladonna (atropine) with or without aloe ensure continuous analgesic effect and reducing of haemorrhage, and furthermore they have antistringent and antiphlogistic effect in haemorrhoids. 1 claim
The present invention relates to the treatment of IgE-mediated disease. The inventors hypothesized that formation of immune complexes between Omalizumab and IgE might be responsible for some of the adverse reactions observed in highly atopic patients (i.e. patients with a history of anaphylaxis and/or high IgE titers). Immune complexes can induce inflammation through activation of Fc gamma receptors (FcγRs) and/or the complement cascade. They identified that Omalizumab:hIgE immune complexes activate human FcγRs in vitro. Moreover, similarly to some of the reported side effects observed in human, Omalizumab:hIgE immune complexes can induce anaphylaxis when injected in mice expressing human FcγRs. Using publicly available omalizumab VH and VL sequences, they cloned and produced two mutant versions of omalizumab in which residues in the Fc portion of the Ab were mutated. These variants did not induce anaphylaxis when injected into mice expressing human FcγRs and could be thus used for the treatment of IgE-mediated disease. Thus invention relates to a recombinant immunoglobulin heavy chain protein which comprises at least one mutation in the Fc portion and recombinant antibody comprising said heavy chain protein.
Background Stress and increased alertness in the evening are major reasons for sleep onset problems, poor sleep and insomnia symptoms. For instance, increased amount of REM, and decreased amount of slow wave sleep may result. Also, the function of sleep in memory consolidation may suffer. They also affect the sleep structure and continuity during the night. They are highly prevalent phenomena among the entire population, including healthy adults and children. However, at the physiological level, the concept of evening alertness is still understudied and often neglected.

Recent advances show that breathing exercise is an efficient tool to reduce stress. However, its use specifically prior to sleep onset and with measurement sleep stages and their microstructures with sleep EEG has been little been studied before. The overall objective of this study is to explore interrelations of stress, learning and sleep quality.
Drug: 68Ga-PSMA-11/68Ga-PSMA-617 Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-PSMA-11/68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-11/68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.